Cargando…

Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients

PURPOSE: No definite conclusion has yet to be reached for the first‐line treatment combined with chemotherapy for advanced adenocarcinoma NSCLC patients with negative driver genes. This study sought to compare the clinical outcomes of Beva+ChT and IO+ChT as first‐line treatment for this population a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Min, Li, Ji, Xu, Shuhui, Li, Yuying, Li, Jiatong, Yu, Jinming, Tang, Xiaoyong, Zhu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028054/
https://www.ncbi.nlm.nih.gov/pubmed/36271595
http://dx.doi.org/10.1002/cam4.5356
_version_ 1784909854970740736
author Wang, Min
Li, Ji
Xu, Shuhui
Li, Yuying
Li, Jiatong
Yu, Jinming
Tang, Xiaoyong
Zhu, Hui
author_facet Wang, Min
Li, Ji
Xu, Shuhui
Li, Yuying
Li, Jiatong
Yu, Jinming
Tang, Xiaoyong
Zhu, Hui
author_sort Wang, Min
collection PubMed
description PURPOSE: No definite conclusion has yet to be reached for the first‐line treatment combined with chemotherapy for advanced adenocarcinoma NSCLC patients with negative driver genes. This study sought to compare the clinical outcomes of Beva+ChT and IO+ChT as first‐line treatment for this population and investigated whether the statuses of BM, PD‐L1 expression, and KRAS and TP53 mutations could influence the results. PATIENTS AND METHODS: The clinical data of patients with adenocarcinoma NSCLC who received first‐line therapy were retrospectively collected and the patients were assigned to the IO+ChT and Beva+ChT groups. The disease control rate (DCR), progression‐free survival (PFS), and overall survival (OS) were evaluated between the two groups. The survival effects of BM, PD‐L1 expression, and KRAS and TP53 mutations were also evaluated. RESULTS: From April 2018 to October 2020, a total of 105 patients with first‐line therapy were included in our analysis; 54 (51.4%) patients were included in the IO+ChT group and 51 (48.6%) patients were included in the Beva+ChT group. The results showed that OS (NR vs. 18.3 m, p = 0.011) and PFS (14.9 m vs. 6.3 m, p < 0.001) were superior in patients in the IO+ChT group than in patients in the Beva+ChT group. Further analysis revealed that the OS (median OS: NR vs. 14.7 months, p = 0.039) and PFS (median PFS: 18.5 vs. 5.5 months, p < 0.001) advantages of the IO+ChT group were also seen in the PD‐L1 > 1% subgroup but were not seen in the PD‐L1 < 1%, BM or KRAS mutation subgroups. CONCLUSIONS: ICIs combined with ChT improved clinical outcomes over Beva combined with ChT as first‐line therapy for adenocarcinoma patients without driver gene alterations, especially in patients with PD‐L1 ≥ 1%.
format Online
Article
Text
id pubmed-10028054
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100280542023-03-22 Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients Wang, Min Li, Ji Xu, Shuhui Li, Yuying Li, Jiatong Yu, Jinming Tang, Xiaoyong Zhu, Hui Cancer Med RESEARCH ARTICLES PURPOSE: No definite conclusion has yet to be reached for the first‐line treatment combined with chemotherapy for advanced adenocarcinoma NSCLC patients with negative driver genes. This study sought to compare the clinical outcomes of Beva+ChT and IO+ChT as first‐line treatment for this population and investigated whether the statuses of BM, PD‐L1 expression, and KRAS and TP53 mutations could influence the results. PATIENTS AND METHODS: The clinical data of patients with adenocarcinoma NSCLC who received first‐line therapy were retrospectively collected and the patients were assigned to the IO+ChT and Beva+ChT groups. The disease control rate (DCR), progression‐free survival (PFS), and overall survival (OS) were evaluated between the two groups. The survival effects of BM, PD‐L1 expression, and KRAS and TP53 mutations were also evaluated. RESULTS: From April 2018 to October 2020, a total of 105 patients with first‐line therapy were included in our analysis; 54 (51.4%) patients were included in the IO+ChT group and 51 (48.6%) patients were included in the Beva+ChT group. The results showed that OS (NR vs. 18.3 m, p = 0.011) and PFS (14.9 m vs. 6.3 m, p < 0.001) were superior in patients in the IO+ChT group than in patients in the Beva+ChT group. Further analysis revealed that the OS (median OS: NR vs. 14.7 months, p = 0.039) and PFS (median PFS: 18.5 vs. 5.5 months, p < 0.001) advantages of the IO+ChT group were also seen in the PD‐L1 > 1% subgroup but were not seen in the PD‐L1 < 1%, BM or KRAS mutation subgroups. CONCLUSIONS: ICIs combined with ChT improved clinical outcomes over Beva combined with ChT as first‐line therapy for adenocarcinoma patients without driver gene alterations, especially in patients with PD‐L1 ≥ 1%. John Wiley and Sons Inc. 2022-10-21 /pmc/articles/PMC10028054/ /pubmed/36271595 http://dx.doi.org/10.1002/cam4.5356 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Wang, Min
Li, Ji
Xu, Shuhui
Li, Yuying
Li, Jiatong
Yu, Jinming
Tang, Xiaoyong
Zhu, Hui
Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
title Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
title_full Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
title_fullStr Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
title_full_unstemmed Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
title_short Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
title_sort immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028054/
https://www.ncbi.nlm.nih.gov/pubmed/36271595
http://dx.doi.org/10.1002/cam4.5356
work_keys_str_mv AT wangmin immunotherapycombinedwithchemotherapyimprovedclinicaloutcomesoverbevacizumabcombinedwithchemotherapyasfirstlinetherapyinadenocarcinomapatients
AT liji immunotherapycombinedwithchemotherapyimprovedclinicaloutcomesoverbevacizumabcombinedwithchemotherapyasfirstlinetherapyinadenocarcinomapatients
AT xushuhui immunotherapycombinedwithchemotherapyimprovedclinicaloutcomesoverbevacizumabcombinedwithchemotherapyasfirstlinetherapyinadenocarcinomapatients
AT liyuying immunotherapycombinedwithchemotherapyimprovedclinicaloutcomesoverbevacizumabcombinedwithchemotherapyasfirstlinetherapyinadenocarcinomapatients
AT lijiatong immunotherapycombinedwithchemotherapyimprovedclinicaloutcomesoverbevacizumabcombinedwithchemotherapyasfirstlinetherapyinadenocarcinomapatients
AT yujinming immunotherapycombinedwithchemotherapyimprovedclinicaloutcomesoverbevacizumabcombinedwithchemotherapyasfirstlinetherapyinadenocarcinomapatients
AT tangxiaoyong immunotherapycombinedwithchemotherapyimprovedclinicaloutcomesoverbevacizumabcombinedwithchemotherapyasfirstlinetherapyinadenocarcinomapatients
AT zhuhui immunotherapycombinedwithchemotherapyimprovedclinicaloutcomesoverbevacizumabcombinedwithchemotherapyasfirstlinetherapyinadenocarcinomapatients